期刊文献+

瑞巴派特联合奥美拉唑对胃镜下糜烂性胃炎的影响 被引量:4

Effect of chronic erosive gastritis patients treated with Rebamipide combined with Omeprazole
下载PDF
导出
摘要 目的探讨瑞巴派特联合舆美拉唑对糜烂性胃炎胃镜下糜烂愈合的改善情况。方法连续收集就诊患者70例纳入临床观察,随机分为治疗组(35例)和对照组(35例)。治疗组采用瑞巴派特联合奥美拉唑肠溶片口服治疗,对照组单用奥美拉唑肠溶片口服治疗,分别于治疗第2、3、4周观察临床症状改善情况及治疗前后胃镜下胃炎愈合情况。结果经过4周治疗,治疗组临床症状缓解率94.2%(P<0.05),对照组临床症状缓解率82.9%(P<0.05),而两组相比有显著性差异(P<0.05)。治疗结束后,对照组与治疗组胃镜下黏膜糜烂愈合有效率分别为80.0%和91.4%,后者有更高的黏膜愈合能力(P<0.05),两组均未见明显副作用。结论瑞巴派特联用奥美拉唑有利于慢性糜烂性胃炎黏膜糜烂的愈合及症状的改善。 Objective To explore the efficacy of rebamipide and omeprazole in the treatment of the chronic erosive gastritis, and to evaluate the healing quality of erosion. Methods 70 patients with chronic erosive gastritis were divided into two groups randomly and equally. The control group was treated with omeprazole and the therapy greul~ was treated with rebam- ipide plus omeprazole. Both groups were treated for 4 successive weeks. The symptoms were assessed before and 2,3,4 weeks after the treatment, as well as endoscopic examination were conducted before and after the treatment. Results The total remis- sion rate of symptoms was 82.9% in the control group ,which was 94.2% in the therapy group. There was a significant differ- ence between two groups( P 〈 0.05 ). In addition, the recovery rate of mucosal erosion in the control group was 80.0%, and it was 91.4% in the therapy group. The latter got better recovery of mucosa. We did not found obvious side effects in both groups. Conclusion Rebamipide plus omeprazole is beneficial for recovery of erosive gastric mueosa and improvement of dyspepsia symptoms.
出处 《中国医学创新》 CAS 2010年第26期12-14,共3页 Medical Innovation of China
关键词 瑞巴派特 胃镜 糜烂性胃炎 黏膜糜烂 Rebamipide Gastroscopy Erosive gastritis Mucosal erosion
  • 相关文献

参考文献5

二级参考文献29

  • 1姒健敏.消化性溃疡的愈合质量[J].中华消化杂志,2005,25(2):127-128. 被引量:103
  • 2杨雪松,李益农.溃疡愈合质量的研究现状[J].中华内科杂志,1995,34(4):270-276. 被引量:46
  • 3李晓波,刘文忠.功能性消化不良的病因和发病机制[J].胃肠病学,2006,11(1):50-52. 被引量:45
  • 4陈晓宇,施尧,马耀宙,彭延申.铝碳酸镁咀嚼片联合奥美拉唑治疗活动性胃溃疡组织学愈合质量的评价[J].胃肠病学,2006,11(3):148-151. 被引量:23
  • 5陈灏珠.实用内科学(第10版)[M].北京:人民卫生出版社,1998.1765-1767.
  • 6李兆申,许国铭,湛先保.胃黏膜损伤与保护的研究历史、现状及意义.李兆申,湛先保,许国铭主编.胃黏膜损伤与保护-基础与临床.上海:上海科学技术出版社,2004.1~9.
  • 7Tarnawski A,Hollander D,Krause WJ,et al."Healed"experimental gastric ulcers remain histologically and ultrastructurally abnormal.J Clin Gastroenterol,1990,12 Suppl 1:S139-S147.
  • 8Tarnawski A,Stachura J,Krause WJ,et al.Quality of gastric ulcer healing:a new,emerging concept.J Clin Gastroenterol,1991,13 Suppl 1:S42-S47.
  • 9Dixon MF,Genta RM,Yardley JH,et al.Classification and grading of gastritis.The updated Sydney System.International Workshop on the Histopathology of Gastritis,Houston 1994.Am J Surg Pathol,1996,20(10):1161-1181.
  • 10Haruma K,Ito M,Kido S,et al.Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis.Dig Dis Sci,2002,47 (4):862-867.

共引文献606

同被引文献47

  • 1施宏,王聚新,杨淑清,陈素玉,谢招飞,黄贺.小剂量奥美拉唑联合瑞巴派特治疗Helicobecter pylori相关慢性浅表性胃炎临床研究[J].胃肠病学和肝病学杂志,2006,15(4):414-415. 被引量:16
  • 2沈健,施瑞华,张国新,郝波,林艳.膜固思达治疗慢性糜烂性胃炎的疗效观察[J].南京医科大学学报(自然科学版),2007,27(3):260-263. 被引量:4
  • 3刘思良,田字彬,刘希双,武军,孔心涓.瑞巴派特治疗慢性糜烂性胃炎疗效观察[J].中国全科医学,2007,10(10):790-792. 被引量:9
  • 4张金卓,郝英霞,齐红兵.瑞巴派特对慢性活动性胃炎前列腺素E_2及白介素-8含量的影响[J].中国药业,2007,16(23):56-57. 被引量:4
  • 5Fujioka T, Arakawa T, Shimoyama T, et al. Effects of rebamipide, a gastro-protective drug on the Helicobaeter pylori status and inflamma- tion in the gastric mucosa of patients with gastric ulcer: a randomized double-blind placebo-controlled multicentre trial [ J]. Aliment Pharma- col Ther, 2003, 18 Suppl 1 : 146-152.
  • 6Nebiki H, Higuehi K, Arakawa T, et al. Effect of rebamipide on Heli- cobacter pylori infection in patients with peptic ulcer [ J]. Dig Dis Sei, 1998, 43(9 Suppl) : 203S-206S.
  • 7Zhang S, Qing Q, Bai Y, et al. Rebamipide helps defend against non- steroidal anti-inflammatory drugs induced gastroenteropathy: a system- atic review and meta-analysis [J]. Dig Dis Sci, 2013, 58(7) : 1991- 2000.
  • 8Satoh H, Takeuchi K. Management of NSAID/aspirin-induced small intestinal damage by GI-sparing NSAIDs, anti-ulcer drugs and foodconstituents [J]. Curt Med Chem, 2012, 19(1) : 82-89.
  • 9Takeuchi K, Kato S, Amagase K. Gastric ulcerogenic and healing im- pairment actions of alendronate, a nitrogen-containing bisphosphonate - prophylactic effects of rebamipide [ J]. Curr Pharm Des, 2011, 17 (16) : 1602-1611.
  • 10Hahm KB, Lee KJ, Kim YS, et al. Quantitative and qualitative useful- ness of rebamipide in eradication regimen of Helicobacter pylori [ J ]. Dig Dis Sci, 1998, 43(9 Suppl) : 192S-197S.

引证文献4

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部